Handelsbanken Fonder’s Enliven Therapeutics ELVN Stock Holding History

Handelsbanken Fonder’s Portfolio ELVN Stock Details ELVN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$878K	Buy	+17,300	New	+$734K	﹤0.01%	1192

Other funds holding ELVN

Pictet Asset Management Carouge, Switzerland $105B AUM 38.07% 1-Year Est. Return

Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

TD Asset Management Toronto, Ontario, Canada $115B AUM 41.58% 1-Year Est. Return

Russell Investments Group London, United Kingdom $114B AUM 41.71% 1-Year Est. Return

New York State Common Retirement Fund Albany, New York $79.3B AUM 43.63% 1-Year Est. Return

LCM

Legato Capital Management San Francisco, California $1.21B AUM 82.36% 1-Year Est. Return

Tema ETFs New York $3.09B AUM 72.72% 1-Year Est. Return

Citigroup New York $303B AUM 53.02% 1-Year Est. Return

Handelsbanken Fonder's ELVN Position: Q2 2026 in Review

Handelsbanken Fonder opened a new position in Enliven Therapeutics (ELVN) in Q2 2026: 17,300 shares worth $878K. The stake represents ﹤0.01% of the portfolio and ranks #1192 among its holdings.

38 funds tracked by Wall St. Rank hold ELVN as of Q2 2026.

Handelsbanken Fonder held 17,300 shares of Enliven Therapeutics worth $878K as of Q2 2026.
Enliven Therapeutics was a new Handelsbanken Fonder position in Q2 2026.
Enliven Therapeutics made up ﹤0.01% of Handelsbanken Fonder's portfolio in Q2 2026, its #1192 holding.
38 funds tracked by Wall St. Rank held Enliven Therapeutics as of Q2 2026.

Based on Handelsbanken Fonder's 13F filing for Q2 2026, filed 10 Jul 2026.